The current therapeutic approach for AD remains primarily symptomatic, focusing on acetylcholinesterase inhibitors (AChEIs) such as donepezil, galantamine, and rivastigmine, alongside the N-methyl-D-aspartate receptor (NMDAR) antagonist memantine . These treatments are often complemented with adjunct therapies, including antidepressants, anxiolytics, and antipsychotics (with a few examples shown in the Figure ) . Recently, the therapeutic field has expanded with the accelerated approval of disease-modifying agents by the Food and Drug Administration (FDA), namely lecanemab (2023) and donanemab (2024) . These monoclonal antibodies, which target amyloid-beta (Aβ) aggregation, have demonstrated modest benefits by slowing cognitive decline in the early stages of AD . However, their global approval is currently restricted, as further clinical evidence is required to fully assess their efficacy .